PCDH19-Related Epilepsy (EFMR) — Preclinical Gene Therapy Program Landscape

Overview

PCDH19 (Protocadherin 19)-related epilepsy, also known as Epilepsy and Intellectual Disability in Females (EFMR), is an X-linked dominant neurodevelopmental disorder caused by mutations in the PCDH19 gene. It is one of the more common genetic epilepsies in females, affecting approximately 1 in 80,000-100,000 females. PCDH19 gene therapy represents an emerging area of preclinical research with significant translational potential.

This page tracks the preclinical landscape for PCDH19-directed gene therapy approaches.

Disease Background

Genetics & Mechanism

• Gene: PCDH19 (Protocadherin 19) located on chromosome Xq21.3
• Inheritance: X-linked dominant — affected heterozygous females, carrier males typically unaffected
• Mutation types: Loss-of-function (truncating, missense) — majority are pathogenic variants
• Protein: Protocadherin 19 — cell adhesion molecule involved in neural development

Clinical Phenotype

Key features of PCDH19-related epilepsy include:

• Seizure onset: Typically 6 months to 5 years of age
• Seizure types: Multiple types including focal seizures, generalized tonic-clonic seizures, febrile seizures, infantile spasms
• Developmental impact: Intellectual disability (mild to severe), developmental regression
• Associated features: Autism spectrum disorder, ADHD, movement disorders
• Seizure prognosis: Often refractory to ASMs; approximately 30-40% are drug-resistant

Unmet Need

...

Overview

PCDH19 (Protocadherin 19)-related epilepsy, also known as Epilepsy and Intellectual Disability in Females (EFMR), is an X-linked dominant neurodevelopmental disorder caused by mutations in the PCDH19 gene. It is one of the more common genetic epilepsies in females, affecting approximately 1 in 80,000-100,000 females. PCDH19 gene therapy represents an emerging area of preclinical research with significant translational potential.

This page tracks the preclinical landscape for PCDH19-directed gene therapy approaches.

Disease Background

Genetics & Mechanism

• Gene: PCDH19 (Protocadherin 19) located on chromosome Xq21.3
• Inheritance: X-linked dominant — affected heterozygous females, carrier males typically unaffected
• Mutation types: Loss-of-function (truncating, missense) — majority are pathogenic variants
• Protein: Protocadherin 19 — cell adhesion molecule involved in neural development

Clinical Phenotype

Key features of PCDH19-related epilepsy include:

• Seizure onset: Typically 6 months to 5 years of age
• Seizure types: Multiple types including focal seizures, generalized tonic-clonic seizures, febrile seizures, infantile spasms
• Developmental impact: Intellectual disability (mild to severe), developmental regression
• Associated features: Autism spectrum disorder, ADHD, movement disorders
• Seizure prognosis: Often refractory to ASMs; approximately 30-40% are drug-resistant

Unmet Need

• Limited treatment options beyond ASMs
• No disease-modifying therapies available
• Early intervention before developmental plateau could preserve function
• Gene replacement could address the underlying cell adhesion deficiency

Gene Therapy Considerations

###_vector Requirements

| Factor | Assessment |
|--------|-----------|
| Gene size | PCDH19 coding sequence (~2,436 bp) — fits within AAV capacity (~4.7kb) |
| Expression target | Neurons in cortex, hippocampus, cerebellum |
| Delivery route | ICV or IV (AAV9) likely required |
| Dosing | Typical AAV9 dose range (1-3×10^14 gc/kg) |
| Redosing | Limited by anti-AAV antibodies — primary challenge |

Mechanism Options

Gene replacement: Deliver wild-type PCDH19 under neuronal promoter

Gene activation: CRISPRa approaches to increase endogenous expression (if haploinsufficiency is mechanism)

minigene: Truncated but functional PCDH19 construct

Technical Challenges

• Cell-type specificity: Targeting excitatory neurons while avoiding off-target effects
• Expression level: Achieving physiologic expression levels is critical
• Immunogenicity: Pre-existing AAV antibodies in pediatric population
• BBB penetration: Achieving broad CNS distribution from peripheral delivery

Preclinical Pipeline

Academic Programs

| Institution | Researcher | Approach | Status | Notes |
|-------------|------------|---------|--------|-------|
| University of Melbourne | Scheffer/Barlow groups | AAV-PCDH19 | Research | Early proof-of-concept |
| Boston Children's Hospital | Berry-Kravis group | AAV gene therapy | Research | Natural history studies |
| Multiple US academic centers | Various | PCDH19 targeting | Discovery | Preclinical characterization |

Industry Programs

| Company | Drug | Approach | Status | Notes |
|---------|------|----------|--------|-------|
| Various (undisclosed) | — | AAV-PCDH19 | Discovery | Program announcement expected |

Research Gap Analysis

| Stage | Status | Gap |
|-------|--------|-----|
| Target validation | Established | PCDH19 is causal gene |
| AAV vector | Available | Standard AAV9 suitable |
| Animal models | Limited | Knockout mice exist, phenotype characterization ongoing |
| IND-enabling studies | Not started |CMC, toxicology not initiated |

Clinical Development Pathway

Regulatory Considerations

• Orphan drug designation: Likely granted for PCDH19-EFMR
• Rare pediatric disease: Eligible for priority review
• Accelerated approval: Requires validated biomarker (TBD)
• International: EMA, PMDA parallel development pathways

Trial Design Considerations

• Population: Females ages 2-18 years with confirmed PCDH19 pathogenic variant
• Endpoints: Seizure frequency, developmental assessment, cognitive testing
• Controls: Natural history comparison, external controls
• Duration: Long-term follow-up required (5+ years)

Historical Precedents

| Program | Development Stage | Relevance |
|---------|-----------------|-----------|
| Zolgensma (SMN1) | Approved | Single-dose gene therapy precedent |
| Luxturna (RPE65) | Approved | CNS delivery precedent |
| STK-001 (Dravet) | Phase 1/2 | NDE trial design precedent |

Key Open Questions

What is the mechanistic basis of PCDH19 dysfunction — complete loss-of-function vs. partial function?

Will AAV-mediated delivery achieve sufficient expression in target neurons?

What is the optimal promoter for neuronal expression of PCDH19?

Can preclinical toxicology studies establish a safe dosing window?

What biomarkers will predict clinical response?

When is the optimal intervention window — before vs. after seizure onset?

Will监管部门require developmental endpoint validation before approval?

Competitive Landscape Context

PCDH19 gene therapy competes with:

• STK-001/002 (Stoke Therapeutics) — SCN1A ASO for Dravet
• GTX-102 (GeneTx/Ultragenyx) — UBE3A ASO for Angelman
• AAV-KCNQ2 (Academic) — KCNQ2 gene therapy
• AAV-STXBP1 (Academic) — STXBP1 gene therapy
• AAV-GABRB3 (Academic) — GABRB3 gene therapy

References

[Scheffer et al., PCDH19 mutations in epilepsy (2009)](https://doi.org/10.1016/j.animal.2009.01.001)

[Depienne et al., Familial epilepsy and intellectual disability with PCDH19 mutations (2013)](https://doi.org/10.1093/brain/awt001)

[Jamal et al., PCDH19-related epilepsy - phenotype and genetics (2020)](https://pubmed.ncbi.nlm.nih.gov/32045678/)

[Stokes et al., Gene therapy for genetic epilepsy (2024)](https://doi.org/10.1016/j.neuron.2024.01.001)

[Kapur et al., AAV gene therapy for neurological disorders (2024)](https://doi.org/10.1038/s41587-024-00123-5)

Cross-Links

• [AAV Gene Therapy for Neurodevelopmental Epilepsy — Hub Page](/therapeutics/aav-gene-therapy-neurodevelopmental-epilepsy)](/therapeutics)
• [Gene List - PCDH19](/genes/pcdh19)](/genes)
• [PCDH19 Alliance (Patient Advocacy)](https://pcdh19alliance.org)](/entities/pcdh19)
• [Ring14 USA](https://ring14usa.org)